Drugs online research references
Chemotherapy. 1996 Mar-Apr;42(2):140-5.
Therapeutic efficacy of intravenous and oral ciprofloxacin in experimental murine infections.
Nishino T, Obana Y.
Department of Microbiology, Kyoto Pharmaceutical University, Japan.
The therapeutic efficacy of intravenous ciprofloxacin against experimentally induced systemic, respiratory tract and urinary tract infections was investigated in mice. The 50% effective dose (ED50) of intravenous ciprofloxacin against experimental systemic infections with Staphylococcus aureus Smith, Escherichia coli 444, Klebsiella pneumoniae KC-1, Serratia marcescens T-55 and Pseudomonas aeruginosa 15846 in mice, were 0.538, 0.0625, 0.0941, 0.294 and 7.76 mg/kg, respectively. These excellent results are equal to 6- to 17-fold the potency following oral administration. In murine respiratory tract infections with K. pneumoniae DT-S, the ED50 of intravenous ciprofloxacin was 20.1 mg/kg, and 26.2 mg/kg after oral administration. A marked decrease of viable bacteria count in lung was noted at doses above 7.4 mg/kg with intravenous administration. On the other hand, after oral dosing, although a marked decrease in viable bacteria count was observed with doses above 29 mg/kg, no decrease in counts was seen at 118 mg/kg and only a bacteriostatic effect could be noted. The therapeutic efficacy of intravenous ciprofloxacin against experimentally induced urinary tract infections in mice was compared to that after oral dosing by determining viable bacteria count in kidney 24h after inoculation. A dose-proportional decrease in counts was observed with both routes of administration at doses of 1.7, 5.6, 17 and 56 mg/kg. Based on these results, intravenous ciprofloxacin was found to have effects superior to those after oral administration in all infection models studied.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8697889&dopt=Abstract
Pharm Weekbl Sci. 1986 Feb 21;8(1):35-9.
Pharmacokinetics of intravenously administered ciprofloxacin in intensive care patients with acute renal failure.
Dirksen MS, Vree TB.
The pharmacokinetics of ciprofloxacin after a single intravenous administration of 100 mg were studied in intensive care patients with an acute renal impairment. There was no correlation found between the creatinine clearance and the renal clearance of ciprofloxacin. This applies to the entire group of patients. The decrease in renal clearance of ciprofloxacin was, however, more pronounced than the change in the elimination half-life, suggesting an important extra-renal elimination of the drug.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2938069&dopt=Abstract
J Antimicrob Chemother. 1988 Nov;22(5):715-20.
Pharmacokinetics of intravenous ciprofloxacin at three different doses.
Ljungberg B, Nilsson-Ehle I.
Department of Infectious Diseases, University of Lund, Sweden.
The pharmacokinetics of ciprofloxacin were evaluated after single iv bolus injections of 50, 100 and 250 mg in eight young, healthy male volunteers. Concentrations were determined by high-performance liquid chromatography. The mean terminal half-life was 3.33, 3.73 and 3.45 h for 50, 100 and 250 mg doses, respectively. No significant differences between the three dose levels were noted for terminal half-life, total and renal clearances, distribution volume (Vd(ss] and percentage of dose recovered in urine over 24 h. The areas under the serum concentration curves were proportional to the given dose. We conclude that distribution and elimination of ciprofloxacin is not dose dependent.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3209529&dopt=Abstract
online pharmacies ||
Hair Million herbal formula for hair loss and hair growth ||
Amoxicillin ||
Tramadol ||
Paxil ||
Rx Drugs USA, Prescription Drugs Online Pharmacy ||
Zithromax ||
online pharmacy ||
Antibiotics and prescription medications online literature ||
Antibiotics